Tirzepatide is Eli Lilly's GLP-1/GIP dual agonist, sold as Mounjaro for type-2 diabetes and Zepbound for obesity. The Phase 3 SURMOUNT and SURPASS programs established it as the most potent incretin therapy approved.
SURMOUNT-5, the head-to-head against semaglutide, read out in April 2026 with 21.6% mean weight loss at 72 weeks versus 15.4% for semaglutide; 36.2% of tirzepatide patients hit ≥25% weight loss versus 19.4% on semaglutide. The drug also has FDA approval for moderate-to-severe obstructive sleep apnea via the SURMOUNT-OSA program, and Truveta EHR data presented at OMA 2026 reproduced the head-to-head signal in routine 12-month care.
Like semaglutide, tirzepatide sits on the FDA's April 30, 2026 proposal to exclude branded actives from the 503B bulks list. Stories here track new readouts, the head-to-head economics, and the long compounding fight.
Eli Lilly reported Q1 2026 worldwide revenue of $19.8 billion, up 56% year over year on 65% volume growth partially offset by a 13% price decline. Mounjaro hit $8.66 billion globally (+125%), Zepbound delivered $4.16 billion in U.S. sales (+80%), and reported Q1 EPS jumped 170% to $8.26. Lilly raised 2026 revenue guidance by $2 billion at each end to $82–85 billion and lifted non-GAAP EPS guidance to $35.50–$37.00. The release also recapped five positive Phase 3 readouts, six new Phase 3 starts, and the closings of the Orna, Centessa, Colonia, and Ajax acquisitions in the quarter.
The FDA announced a proposal on April 30 to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, finding no clinical need for large-scale compounding now that branded supply has stabilized. Commissioner Marty Makary said outsourcing facilities cannot lawfully compound from bulk substances when FDA-approved drugs are available unless a clear clinical need exists. Public comments are open through June 29, 2026. The proposal targets 503B outsourcing facilities only and does not directly affect 503A patient-specific compounding, but it forecloses the largest legal pathway for branded-active GLP-1 compounding.
Fractyl Health's REMAIN-1 study — the first blinded, randomized, sham-controlled trial of an endoscopic 'gut reset' procedure — was accepted for presentation at DDW 2026. In 45 adults who had lost ≥15% body weight on tirzepatide and then discontinued, 29 received Revita duodenal mucosal resurfacing and 16 had a sham procedure. At 6 months post-discontinuation, Revita-treated patients regained 4.5% vs 7.5% for sham (P=0.07) — a 40% lower weight regain. Patients with more tissue resurfaced maintained >80% of pre-discontinuation weight loss. Topline pivotal-cohort data expected Q4 2026.
The first definitive Phase 3B head-to-head trial of Lilly's tirzepatide versus Novo Nordisk's semaglutide in 750 patients with obesity over 72 weeks showed tirzepatide produced 21.6% mean weight loss vs semaglutide's 15.4%. 36.2% of tirzepatide patients achieved ≥25% weight loss vs 19.4% on semaglutide. Results published April 20 give Lilly a clear comparative data point in the GLP-1 market share battle.
A University of Colorado Anschutz-led secret shopper study presented at Obesity Medicine Association 2026 surveyed 75 weight-loss clinics and medspas across two US states. 69 of 74 still offered compounded semaglutide and 65 of 74 offered compounded tirzepatide despite FDA resolving the name-brand shortages. Four source facilities had received FDA warnings or state licensing discipline since 2023 — three related to sterile compounding. Many clinics report using 'additive' formulations to skirt compounding restrictions.
The FDA published updated guidance clarifying compounding requirements now that semaglutide and tirzepatide shortages have been resolved. The statement reaffirmed enforcement deadlines for 503A and 503B pharmacies while acknowledging ongoing legal challenges from the Outsourcing Facilities Association.
A poster at the Obesity Medical Association annual conference (April 10-12, San Diego) showed tirzepatide achieved greater body weight reduction than semaglutide at 12 months in a real-world Truveta EHR analysis of adults with obesity without diabetes, consistent with SURMOUNT-5 clinical trial results.
A Mass General Brigham study of over 90,000 HFpEF patients published in JAMA found semaglutide reduced heart failure hospitalization or all-cause mortality by 42%, while tirzepatide achieved a 58% risk reduction compared with sitagliptin. Both drugs showed acceptable safety profiles with benefits appearing early in treatment.
A study in Scientific Reports found that early intervention with tirzepatide or semaglutide significantly reduced atherosclerotic plaque formation in ApoE-knockout mice, suggesting GLP-1 drugs may have preventive cardiovascular benefits beyond their metabolic effects when initiated before disease progression.
A federal grand jury indicted Utah osteopathic physician Justin Bradley Watkins for obtaining non-FDA-approved peptides including tirzepatide, semaglutide, BPC-157, and retatrutide from a Chinese supplier, affixing fake labels, and selling them to over 200 patients without disclosing their unapproved status.
Stanford researchers found approximately 10% of people may have resistance to GLP-1 drugs, limiting effectiveness for glucose regulation and weight loss. The study examined individual variation in how GLP-1 drugs slow gastric emptying.
Phase 3 SURMOUNT-4 data show patients who continued tirzepatide achieved further weight loss, while those switched to placebo regained ~14% body weight over 52 weeks. Findings underscore the need for long-term GLP-1/GIP therapy continuation.
Researchers analyzed 410,198 Reddit posts mentioning semaglutide or tirzepatide, finding 43.5% of 67,008 self-reported users described at least one side effect extending beyond clinical trial data.
Semaglutide injections officially removed from the FDA drug shortage list, though localized availability issues persist. Tirzepatide shortage status remains contested by the Outsourcing Facilities Association.
A large GWAS study published in Nature identified a missense variant in GLP1R predicting an additional 0.76 kg of weight loss per allele copy. GIPR variation was linked to nausea/vomiting side effects specific to tirzepatide users.
Tirzepatide (Mounjaro) Indian sales fell to ₹114 crore in March from ₹135 crore in February, while semaglutide sales rose to ₹59 crore. Semaglutide's GLP-1 segment share jumped to 33% from 25% as dozens of generics flood the market.
Research in JAMA Network Open shows semaglutide, tirzepatide, and bariatric surgery all produce substantial fat mass reduction but also cause reductions in lean mass over 24 months, highlighting the body composition tradeoff in GLP-1 treatment.
Based on analysis of 107,910 patients, the FDA concluded there is no increased suicide risk associated with GLP-1 medications and has requested removal of related warning labels.